Natixis’s Terns Pharmaceuticals TERN Stock Holding History

Natixis’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,800	Closed	-$148K	–	1360
2026 Q1	$148K	Buy	+2,800	New	+$115K	﹤0.01%	930

Other funds holding TERN

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Natixis's TERN Position: Q2 2026 in Review

Natixis sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,800 shares — an estimated $148K sold.

Natixis first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $148K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Natixis reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Natixis sold 2,800 Terns Pharmaceuticals shares in Q2 2026, an estimated $148K.
Natixis first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Natixis's Terns Pharmaceuticals position peaked at $148K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.